Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors

Journal of Surgical Research

Volumn 173, Issue 2, 2012, Pages 320-326

  Cho, Nancy L ^a   Carothers, Adelaide M ^a   Rizvi, Hira ^a   Hasson, Rian M ^a   Redston, Mark ^a   Bertagnolli, Monica M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

catenin; aggressive fibromatosis; desmoid tumor; tyrosine kinase; Wnt signaling

Indexed keywords

BETA CATENIN; PROTEIN HYDROLYSATE; PROTEIN TYROSINE KINASE;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DESMOID TUMOR; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; ONCOGENE C KIT; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR LOCALIZATION;

ADULT; BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84858281427     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2010.10.037     Document Type: Article

References (32)

1. Klemmer S, Pascoe L, DeCosse J. Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. Am J Med Genet 1987;28:385.
2. Nichols RW. Desmoid tumors: A report of thirty-one cases. Arch Surg 1923;7:227.
3. Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, et al. Desmoid tumors in patients with familial adenomatous polyposis. Cancer 1994;74:1270.
4. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612.
5. Klein WA, Miller HH, Anderson M, et al. The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 1987;60:2863.
6. Ballo MT, Zagars GJ, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1998; 42:1007.
7. Bertagnolli MM, Morgan JA, Fletcher CD, et al. Multimodality treatment of mesenteric desmoid tumors. Eur J Cancer 2008; 44:2404.
8. Kotiligam D, Lazar AJ, Pollock RE, et al. Desmoid tumor: A disease opportune for molecular insights. Histol Histopathol 2008; 23:117.
9. Alman BA, Li C, Pajerski ME, Diaz-Cano S, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151:329.
10. Giarola M, Stagi L, Presciuttini, et al. Screening for mutations of the APC gene in 66 Italian familial adenomatous polyposis patients: Evidence for phenotypic differences in cases with and without identified mutation. Br J Cancer 1998;58:1021.
11. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509.
12. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522.
13. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003;60:4761.
14. Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol 1998;153:709.
15. Danilkovitch-Miagkova A, Miagkov A, Skeel A, et al. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol 2001; 21:5857.
16. Roura S, Miravet S, Piedra J, et al. Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem 1999;274:36734.
17. Kajiguchi T, Lee S, Lee MJ, et al. KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk Res 2008;32:761.
18. Goncalves A, Monges G, Yang Y, et al. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst 2006;98:562.
19. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24:1995.
20. Skubitz KM, Manivel JC, Clohisy DR, et al. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: Case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol 2009;64:635.
21. Heinrich MC, Joensuu H, Demetri GD, et al. Imatinib Target Exploration Consortium Study B2225. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717.
22. Mace J, Sybil Biermann J, Sondak V, et al. Response of extra-abdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373.
23. Moran AE, Hunt DH, Javid SH, et al. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 2004; 279:43261.
24. Weyant MJ, Carothers AM, Bertagnolli ME, et al. Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin Cancer Res 2000;6:949.
25. National Institutes of Health. Image processing and analysis in Java program (ImageJ). Available at: http://rsbweb.nih.gov/ij/. Accessed December 17, 2010.
26. Liegl B, Leithner A, Bauernhofer T, et al. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: Is there a role for tyrosine kinase inhibitors in c-kitnegative desmoid tumors? Histopathology 2006;49:576.
27. Leithner A, Gapp M, Radl R, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005;58:1152.
28. Aleksandrov A, Simonson T. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J Biol Chem 2010;18:13807.
29. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007;13:4874.
30. Moffatt EJ, Kerns BJ, Madden JM, et al. Prognostic factors for fibromatoses: A correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome. J Surg Onc 1997;65:117.
31. Kurtz J-E,Asmane I,VoegeliA-C, et al.AV530Imutation in c-KIT exon 10 is associated with imatinib response in extra-abdominal aggressive fibromatosis. Sarcoma 2010;2010:458156.
32. de Camargo VP, Keohan ML, D'Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010;116:2258.